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Background
Rare bleeding disorders include inherited coagulation disorders except for von 
Willebrand disease and hemophilia A and B. These disorders affect both men and women 
worldwide and mainly have an autosomal recessive pattern of inheritance. Given the 
paucity of cases of rare bleeding disorders, there are limited data regarding some topics 
among bleeding disorders.
Methods
This retrospective study from 2005‒2019 collected demographic data and the causes 
of death among cases with rare bleeding disorders from 2 provinces of Iran.
Results
Overall, 5 deaths were reported, including 3 cases with factor V deficiency, a case with 
factor XIII deficiency, and a case with combined factor V and factor VIII deficiencies. The 
main causes of death were bleeding in the central nervous system (2 cases; 1 with factor 
V deficiency and 1 with combined factor XIII deficiency). Post-partum hemorrhage was 
the cause of death in a woman with factor V deficiency while anaphylaxis shock was the 
cause of death in the case with combined factor V and factor VIII deficiencies. A woman 
with factor V deficiency died from an internal bleeding episode.
Conclusion
Gathering data on the causes of death in rare bleeding disorders through worldwide regis-
tries can be helpful for the management of this rare group of bleeding disorders.
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INTRODUCTION
The rare bleeding disorders (RBDs) comprise inherited 
deficiencies of coagulation factors I, II, V, VII, X, XI, XIII, 
and combined factors V and VIII in the plasma, and combined 
deficiency of vitamin K-dependent factors. Their prevalence 
varies from 1 in 500,000 to 1 in 2–3,000,000 population. 
RBDs comprise approximately 3–5% of all bleeding disorders 
[1]. According to data released by the World Federation 
of Hemophilia (WFH), factor XI and FVII deficiencies have 
the highest prevalence, while factor II deficiency has the 
lowest prevalence [2]. While 65,000 patients with RBDs 
were registered in a European registry through 2010, RBDs 
disorders are expected to be more prevalent in developing 
countries [1] due to the high rates of consanguineous mar-
riages in these countries [3, 4]. Hence, national and interna-
tional data registries have been programmed to gather stand-
ardized data [5]. Most RBDs have autosomal recessive pat-
terns of inheritance; thus, except for hemophilia, RBDs occur 
both in male and female patients [6]. The plasma levels 
of a deficient coagulation factor do not usually reflect or 
predict the severity of hemorrhagic symptoms [7]. However, 
factor XIII, factor X, and fibrinogen deficiencies show an 
association between the levels of coagulation factor activities 
in plasma and the clinical picture of bleeding [8, 9]. The 
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Table 1. Main causes of death and therapeutic regimens in 5 patients with RBD.
Cases Sex Age (yr) Factor levels Cause of death The last therapeutic regimen Treatment/province
FVD-1 F   23 1% Post-hemorrhage FFP On-demand/Khorasan-Razavi
FVD-2 F     2 4% Internal bleeding and hepatomegaly FFP On-demand/Khorasan-Razavi
FVD-3 F     2a) 1% CNS bleeding FFP On-demand/Hamedan
FXIIIDb) M   23 ＜5% CNS bleeding post HCV eradication Fibro+Cryo Pro & On-demand/Hamedan
F58D F   18 7%c), 10%d) Anaphylaxis shock post FF FFP+FVIIIC On-demand/Hamedan
a)Months, b)case infected with hepatitis C virus (HCV), c)factor V level in plasma, d)factor VIII in plasma.
Abbreviations: CNS, central nervous system; Cryo, cryoprecipitate; F58D, factor V and VIII deficiency; FFP, fresh frozen plasma; Fibro, 
fibrogammin; FXIIID, factor XIII deficiency; FVD, factor V deficiency; FVIIIC, factor VIII concentrate; Pro, prophylaxis; RBD, rare bleeding 
disorder.
clinical pictures of bleeding are diverse in RBDs and our 
knowledge of the clinical pictures and therapeutic manage-
ment of bleeding remains unsatisfactory [10]. Compared to 
males with RBDs, women with RBDs have more challenges 
due to more hemorrhagic symptoms secondary to menor-
rhagia, post-partum bleeding, bleeds of ovarian cysts, polyps, 
endometriosis, fibroids, and endometrial hyperplasia. Hence, 
women with RBDs require more care and therapeutic atten-
tion [11, 12]. Until now, post-partum bleeding has been 
considered a leading cause of morbidity and mortality in 
women worldwide [13]. 
The treatment of hemorrhagic episodes and bleeding dur-
ing and after surgeries in patients with RBDs is a challenge 
due to limited experiences. In the face of classical hemophilia 
in developing countries, who make use of prophylaxis regi-
mens [14], patients with RBDs are administered on-demand 
coagulation therapy [15]. Except for coagulation factor VII 
and X concentrates that are commercially available, there 
remain no coagulation factor I, II, V, XI concentrates on 
the market [16]. The mainstay of the treatment in RBDs usually 
comprises fresh frozen plasma (FFP), cryoprecipitates, and 
plasma-derived coagulation factor concentrates [5, 17, 18]. 
The rarity of RBDs has resulted in a paucity of findings 
regarding many aspects of these current disorders, especially 
data related to mortality. The analysis of the causes of death 
of these patients may help to better identify priorities, target 
allocation of limited resources, and tailor preventive efforts 
to decrease morbidity and mortality in RBDs [5, 19]. A search 
for literature available on medical search engines (PubMed 
and Google Scholar) showed no published studies on deaths 
directly attributable to RBDs. 
MATERIALS AND METHODS
To investigate the numbers and causes of death among 
patients with RBDs, a retrospective study was performed 
in two provinces (Hamedan and Khorasan-Razavi) in the 
northwestern and northeastern areas of Iran in July 2019.
This study approved by the Ethics Committee of Hamadan 
University of Medical Sciences (Ethics Code: IR.UMSHA. 
REC.1398.739).
After identifying cases of mortality due to RBD from 2005–
2019 from searches of medical records, a prepared ques-
tionnaire was completed through interviews with the parents 
of the dead patients and or reviewing the medical records 
in the relevant hospitals. The mined data included the pa-
tients’ date of birth, sex, type of RBD, plasma level of the 
deficient coagulation factor, cause of death, date of death, 
place of death, and type of treatment.
RESULTS
The frequencies of factor V, factor XIII, and combined 
factor V and VIII deficiencies in Khorasan Razavi and 
Hamedan provinces were 15%, 14%, and 24% and 1%, 8%, 
and 4% respectively. Overall, 5 dead individuals with RBDs 
were identified. They comprised 4 females and 1 male. Three 
cases were from Hamedan province and 2 cases were from 
Khorasan-Razavi province. They included 3 cases with factor 
V deficiency (the plasma levels of factor V were 1%, 4%, 
and 1%), a case with factor XIII deficiency (＜5% in plasma), 
and a case with combined factor V and VIII deficiencies 
(factor V 7% and factor VIII 10% in plasma). The youngest 
dead patient was a 2- month-old neonate with factor V 
deficiency and the oldest was a 23-year-old male with factor 
XIII deficiency. Their mean and median age was 13.03 and 
18 years, respectively. The earliest death occurred in 2005 
and the most recent in 2012. Three patients had a history 
of having another affected member in their families (1 each 
of factor V deficiency, factor V and VIII deficiencies, and 
factor XIII deficiency). All of the deaths occurred in hospitals 
and cause of death was hemorrhage in 4 cases (Table 1). 
Central nervous system (CNS) hemorrhage was the main 
cause of mortality, occurring in a case with factor V defi-
ciency and a case with factor XIII deficiency. All of the 
dead cases received the relevant coagulation therapy as 
on-demand therapy. The exception was the case with factor 
XIII deficiency, who had received fibrogammin as a prophy-
laxis regimen when fibrogammin was available. This patient 
had received infused cryoprecipitate on-demand when fi-
brogammin was not available. This case with factor XIII 
deficiency was also positive for hepatitis C virus (HCV) 
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infection. He had undergone eradication therapy for HCV 
infection. The CNS bleeding happened while receiving treat-
ment for HCV eradication.
On-demand coagulation therapy was the common ther-
apeutic regimen used for these patients. Two of the 3 patients 
with factor V deficiency had severe disorders (factor V plasma 
levels ＜1%). None of them were on prophylaxis regimens.
DISCUSSION
The RBDs exist in all ethnic populations and are widely 
distributed worldwide. They affect both males and females. 
According to the literature, the prevalence of RBDs is higher 
in the Iranian population compared to that in developed 
countries. Consanguinity unions are a common custom in 
Iran [3, 20]. Nevertheless, RBDs are considered orphan bleed-
ing disorders due to their rarity and dispersion. Moreover, 
there are limited data on many topics including the types 
of genetic defects and treatment strategies. Collecting dis-
perse data under the umbrella of a worldwide registry can 
bridge these gaps. This study collected death-related data 
in patients with RBDs in 2 centers. It is hoped that by 
mining such data, health system defects regarding patients 
with RBDs will be highlighted to allow health system pro-
viders to better program to cover these conditions.
The results of this study do not reflect all deaths of cases 
with RBDs in these 2 regions as other deaths may have 
been missed in our search. One limitation of this study was 
the low number of deaths, which made it challenging to 
interpret the results. Most of the deaths in this study had 
factor V deficiency; however, this deficiency is not the most 
common RBD. Palla et al. [10] reported factor VII deficiency 
(with a prevalence of 37.5%) and factor XI deficiency (with 
a prevalence of 36.5%) to be the most common RBDs 
worldwide. While authors̕ ancient study showed that factor 
VII deficiency is the most common RBD in this region, 
the present study found no reports of death in any cases 
with factor VII deficiency. This may be due to both low 
numbers of included cases as well as differences in bleeding 
severity among RBDs. Moreover, there also was no death 
report for any case with factor XI deficiency, which, again, 
may also be due to the low number of cases and differences 
in bleeding severity among various types of RBDs. These 
findings need to be addressed in further investigations on 
death in RBDs. 
Overall, CNS hemorrhage was the main cause of death, 
occurring in 2 cases with factor V deficiency and a case 
with factor XIII deficiency. These findings show that bleed-
ing in this organ can be dangerous and fatal. Regardless 
of the type of bleeding disorder, CNS bleeds should be consid-
ered an emergency and a vital problem requiring immediate 
treatment. Our findings are compatible with the results of 
an evaluation of the causes of death in hemophilia [19]. 
CNS bleeding can occur spontaneously or as post-trauma. 
Patients with a severe type of RBD are more susceptible 
to spontaneous CNS bleeding. Post-trauma CNS bleeding 
can occur in patients with severe and mild types of RBDs.
All of the reported deaths received on-demand therapy. 
There is no specific coagulation factor concentrate for some 
types of RBDs. These patients usually make use of FFP, 
without the option of prophylaxis regimens, especially in 
developing countries. Nevertheless, there is a possibility for 
prophylaxis for factors VII, X, and XIII deficiencies using 
relevant recombinant coagulation factor concentrates. 
Patients with factor V and combined factor V and VIII 
deficiencies require FFP infusion as a source of coagulation 
factor V for replacement therapy. The administration of FFP 
is associated with disadvantages including volume overload, 
exposure to unwanted plasma proteins, and risk of blood-borne 
viruses. Although the occurrence of anaphylactic shock 
post-FFP infusion is rare, it occurred in a patient with com-
bined factor V and VIII deficiencies in this study and resulted 
in patient death. Hence, FFP should be administered with 
caution and under direct physician supervision. 
There are currently no commercially available recombi-
nant or plasma-derived factor V concentrates, likely due 
to the low frequency of individuals with factor V deficiency 
and subsequent limited commercial market for recombinant 
factor V concentrate. These limitations have resulted in a 
challenge in the treatment of patients with factor V 
deficiency. The manufacturing of recombinant factor V con-
centrate by a pharmaceutical company will allow faster, bet-
ter, and more effective management of bleeding episodes 
in factor V and combined factor V and VIII deficiencies. 
The cause of death in 1 of the patients with factor V deficiency 
was post-partum bleeding that was not controlled using an 
infusion of FFP. This experience underscores that FFP is 
not a fully satisfactory treatment as the amount of factor 
V in each bag is not standardized. 
The case with factor XIII deficiency was positive for HCV 
infection. He had a history of multiple fibrogammin and 
cryoprecipitate infusions. These infusions may be associated 
with risks of the transmission of blood-borne viruses includ-
ing HCV. The patient was receiving an HCV eradication 
regimen using peginterferon when he experienced a fatal 
hemorrhage in his CNS that was not controlled through 
fibrogammin infusion. 
The collection of related information by hemophilia treat-
ment centers and the sharing of these data with a global 
RBDs registry are recommended to improve our knowledge 
about death-related data in RBDs. 
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